Purpose: The aim of this study was the automated synthesis of the mitochondrial membrane potential sensor 4-[
Introduction
Mitochondrial metabolism provides adenosine triphosphate (ATP) as the main source of chemical energy in the cell and produces a myriad of other important co-factors as well as metabolites. Mitochondrial dysfunction has been associated with human diseases such as diabetes [1] , cardiac failure [2] , neurodegenerative diseases [3] , and cancer [4] . There have been rapid advances in the development of tools to study mitochondrial metabolism in vitro during the last decades [5] . Among these tools, monitoring mitochondrial membrane potential (ΔΨ m ) with lipophilic, cationic dyes has emerged as one of the most commonly used techniques [6] . While lipophilic cations have proven good molecular markers of mitochondrial activity, in vivo study of mitochondrial potential requires the development of noninvasive molecular imaging probes.
To harness lipophilic cations for the assessment of ΔΨ min vivo, carbon-11-labeled phosphonium salts were synthesized [7] and studied as imaging probes [8] for positron emission tomography (PET) [9] . The synthesis of 4-[ 
]FBnTP) was later investigated to take advantage of the superior decay properties of fluorine-18 (t 1/2 = 109.8 min, maximum β + energy = 635 keV) [10] . The probe was successfully used in various animal models for imaging of paclitaxel-induced apoptotic activity [11] , unstimulated brown adipose tissue [12] , ischemic areas after transient coronary occlusion [13] , and myocardial perfusion [14] . The original synthesis by Ravert et al. [10] was reported to proceed in four steps, affording the probe in 6 % nondecay corrected (n.d.c.) radiochemical yield (RCY) within 82 min and molar activities (A m ) of 16.7 GBq/μmol. The synthesis was performed manually and no activity yields (AY) were reported. The same group later reported a microwave-facilitated synthesis using custom hardware delivering the probe in n.d.c. RCY of 8.3 % within 52.4 ± 14 min and A m of 534.5 ± 371.4 GBq/μmol [15] . Again, no AY or starting activities were disclosed. Zhang et al. recently described the formation of [ 18 F]FBnTP in one step via copper-mediated 18 F-fluorination using a pinacolyl boronate precursor [16] . Formation of the probe was reported in high RCY of 62 ± 1.4 % before purification. The synthesis was performed manually and neither AY nor A m of the purified product formulation were revealed. Even though metal-mediated 18 F-fluorinations will likely be used for the clinical production of PET imaging probes in the future, their compliance with the principles of current good manufacturing practice (cGMP) has not been extensively established to this date [17] .
In this study, we intended to translate the original fourstep synthesis into a clinically useful production procedure on a commercially available radiosynthesizer that reliably affords multiple doses ready for injection into patients. Since the three-pot design of the ELIXYS FLEX/CHEM radiosynthesizer allows for complete automation of the sequence, it was chosen for this task [18] .
Materials and Methods

Materials
All commercially available reagents and materials were used as received unless otherwise specified. Acetonitrile (MeCN, extra dry, 99.9 %), dimethyl sulfoxide (DMSO, extra dry, 99.7 %), and dichloromethane (DCM, extra dry, 99.9 %) were obtained from Acros Organics. Ethanol (EtOH, 200 proof, anhydrous) was obtained from Decon. All water used was purified to 18 MΩ and p a s s e d t h r o u g h a 0 . 1 -m m f i l t e r . 4 -T r i m e t h ylammoniumbenzaldehyde trifluoromethanesulfonate and 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo [8.8.8] hexacosane (K 222 , 98 %) were purchased from ABX. Triphenylphosphine dibromide (Ph 3 PBr 2 , 96 %; stored and handled in a glovebox), sodium borohydride on alumina (NaBH 4 ⋅(Al 2 O 3 ) x ); stored and handled in a glovebox), and triphenylphosphine (PPh 3 , 99 %) were purchased from Sigma-Aldrich. 4-Fluorobenzyl triphenylphosphonium chloride (FBnTP, nonradioactive reference, 98 %) was purchased from Alfa Aesar. L-Ascorbic acid sodium salt (Naascorbate, 99 %) was purchased from Acros Organics. Potassium carbonate (K 2 CO 3 ) was purchased from FisherChemical. Sodium chloride solution (saline, 0.9 %, injection, USP) was purchased from Hospira. Sep-Pak Plus Accell CM cartridges (preconditioned with EtOH (10 ml), followed by deionized water (20 ml)), Oasis WCX Plus cartridges (preconditioned with EtOH (5 ml), followed by deionized water (10 ml)), Sep-Pak Light Plus QMA cartridges (preconditioned with 0.5 N KHCO 3 (3 ml), followed by deionized water (5 ml)), and Sep-Pak Classic Silica cartridges (wetted with DCM (3 ml)) were purchased from Waters. Grace™ SCX MaxiClean cartridges (wetted with deionized water (5 ml)) were purchased from Alltech. Millex-GV (SLGV013SL and SLGV004SL) sterile filters with a 0.22-μm pore size hydrophilic PVDF membrane were purchased from MilliporeSigma. Reactor vials (W986259NG), reagent vial septa (224100-072), and crimp caps (224177-01) were purchased from Wheaton. Reagent vials (62413P-2) were purchased from Voigt. Magnetic stir bars (14-513-65) were purchased from Fisher Scientific. Glass chromatography columns (006SCC-10-10-AA) were purchased from Omnifit Labware.
Chromatography and Analytical Methods
Radio thin layer chromatography (radio-TLC) was performed on silica plates (TLC Silica gel 60 W F 254 s, Merck). After spotting a small sample volume (~1-5 μl) using a glass capillary, the plate was developed in the mobile phase (MeCN). Chromatograms were obtained using a radio-TLC scanner (miniGita Star, Raytest). Radio high-performance liquid chromatography (radio-HPLC) chromatograms for quality control were registered using a 1200 Series HPLC system (Agilent Technologies) equipped with a GabiStar flow-through gamma detector (Raytest). Data acquisition and processing was performed using OpenLAB CDC ChemStation Edition 2016 (Agilent Technologies). Analytical HPLC was used to estimate the radiochemical purity (RCP), the A m , and the chemical purity of final formulations of [ RCP was calculated by dividing the area under the curve (AUC) for the desired product by the sum of AUC for all peaks. To confirm the structural identity of the synthesized compound, a radioactive sample (195 μl) of the final formulation was diluted with a 10-mM solution of the nonradioactive reference in water (5 μl) and injected for HPLC analysis (5 μl injection volume). Calibration curves of UV absorbance versus molar mass were created in advance for calculating A m (Suppl. Fig. 1 ). Curves were obtained using a linear-least square fit of absorbance versus molar mass for six data points spanning the expected molar mass range. A m was calculated by dividing the radioactivity of the injected sample by the molar mass (as determined from the AUC for the UV peak and the calibration curve). 
Radiosynthesizer Setup
Dedicated cassettes for [ 18 F]FBnTP synthesis were reused, and liquid pathways cleaned with MeCN before each experiment using an automated sequence (Suppl. section 2 and Suppl. BFBnTP_cassette-cleaning_sequence^). The cleaned cassettes were loaded into the synthesizer and locked into position. Clean reactor vials with a magnetic stir bar were placed in the reactor positions. Shortly before the start of the synthesis, reagent vials were filled with the appropriate reagents and then sealed with a septum and crimp cap. Once sealed, the reagent vials were inverted and loaded into the appropriate cassette reagent positions. Preconditioned cartridges and the glass column for the reduction step were installed on the cassettes using Luer fittings in the positions indicated in Fig. 1 . Interconnections were made as indicated in Fig. 1 . Finally, a mixture of EtOH (~50 ml) and ice was added to the vacuum trap Dewar.
Synthesis Protocol
No-carrier-added [ 18 O]H 2 O (~97 % isotopic purity, Medical Isotopes) in a RDS-112 cyclotron (Siemens) at 11 MeV using a 1-ml tantalum target with Havar foil. The activity was unloaded from the target and pushed through a strong cation exchange (SCX) cartridge (if applicable) before entering the QMA cartridge. Trapped [
18 F]fluoride was subsequently eluted with a solution of K 222 (10 mg, 27 μmol) and K 2 CO 3 (1 mg, 7 μmol) in acetonitrile/water (3:5, 0.8 ml) into the first reaction vessel (1.5 min, 7 psig nitrogen pressure). Contents were partially evaporated while applying vacuum and a stream of nitrogen (10 psig) at 110°C for 3.5 min with stirring. Acetonitrile (1.2 ml) was added through the QMA cartridge to wash residual activity into the vessel, and the combined contents evaporated for 3.0 min at 110°C (7 psig nitrogen pressure). Acetonitrile (1.2 ml) was directly added to the reactor, and the contents were fully evaporated for 2.5 min at 110°C (7 psig nitrogen pressure). The reactor was cooled to 35°C, and a solution of 4 -t r i m e t h y l a m m o n i u m b e n z a l d e h y d e trifluoromethanesulfonate (5 mg) in DMSO (0.8 ml) was added. Contents were reacted at 90°C for 5 min with stirring. A 1 % (w/v) Na-ascorbate solution (3 ml followed by 2 ml) was added to the reactor under stirring, and the resulting mixture was passed through an Oasis WCX cartridge over a period of 1.5 min (6 psig nitrogen pressure). Another batch of 1 % (w/v) Na-ascorbate solution (3 ml followed by 2 ml) was added to the reactor and passed through the cartridge. The cartridge was blow-dried for 1 min (20 psig nitrogen pressure) and eluted with DCM (3 ml). The mixture was passed through a glass chromatography column, containing NaBH 4 ⋅(Al 2 O 3 ) x (350 mg) followed by K 2 CO 3 (2 g) and directed into the second reaction vessel (3 psig nitrogen pressure). Cartridge and column were rinsed with DCM (1 ml, containing 0.2 % (v/ v) of water) (3 psig nitrogen pressure). A solution of Ph 3 PBr 2 (100 mg) in DCM (1.1 ml) was added to the second reaction vessel and the mixture was reacted at 35°C for 10 min. All contents of the second reaction vessel were passed through a (3 mg) in EtOH (0.6 ml) was added to the third reaction vessel, and all contents were partially evaporated to approximately 2 ml by applying both vacuum and a stream of nitrogen (3 psig) at 45°C for 3.5 min with stirring. The silica cartridge was rinsed with DCM (1 ml) (1 psig nitrogen pressure), and the contents of the third reaction vessel were partially evaporated to approximately 0.5 ml by applying both vacuum and a stream of nitrogen (3 psig) at 45°C for 6.5 min with stirring. EtOH (1 ml) was added and the contents were partially evaporated to approximately 0.5 ml by applying both vacuum and a stream of nitrogen (7 psig) at 80°C for 2.5 min with stirring. The resulting mixture was reacted in a sealed position at 160°C for 5 min with stirring. The reaction vessel was cooled to 35°C and water (3 ml) was added with stirring. The resulting mixture was passed through a Sep-Pak Plus Accell CM cartridge (8 psig nitrogen pressure). The Sep-Pak was immediately washed with EtOH (20 ml) and the product released with 2 % EtOH in saline + 0.5 % (w/v) Na-ascorbate (10 ml) and directed through a sterile filter into a vented sterile vial.
Results
The aim of this study was to develop a reliable synthesis protocol for the potentiometric PET-probe [
18 F]FBnTP on a commercially available radiosynthesizer. For practical clinical translation, the final formulation should be injectable, i.e., pass all applicable quality control tests, and should be obtained in AY that allow for imaging of multiple patients. To achieve these goals, we adapted a four-step, three-pot synthesis [10] by assembling a sequence of Bunit operations^(e.g., Btrap,B elute,^Bevaporate,^Breact^) that are programmed into the synthesizer-software and specifying the parameters for each (e.g., temperature, reaction time, pressure) [19] . A seamless flow of solvents was tested in abbreviated runs without activity or reagents to ensure its correctness. The sequence was optimized for RCY and RCP during several production runs (n = 24) using activity amounts that averaged around 30.8 GBq. Adjustments to the sequence were made based on careful analysis of the crude product composition as well as the residual activity retrieved from vital parts of the setup (i.a. reactors, SPE-cartridges, and waste containers). We also performed low-activity test runs starting with an average of 300 MBq of [ 18 F]fluoride which allowed for safe withdrawal of samples for radio-HPLC as well as radio-TLC analysis between each step. The reaction vessel was made accessible between steps by using the BMove Reactor^operation (Suppl. BFBnTP_low-activity-production_sequence^). The optimized sequence consists of 33 Bunit operations^and runs autonom o u s l y w i t h o u t u s e r i n t e r f e r e n c e ( S u p p l . BFBnTP_production_sequence^). The synthesis includes intermediate solid-phase extraction purifications, an on-column reduction, controlled solvent evaporation steps, and reactions in sealed position at temperatures above the boiling points of the respective solvents. An overview of the synthesizer setup as well as the flow of liquids is depicted in Fig. 1 . The SPE purification with a Sep-Pak Plus Accell CM cartridge is supported by two electrically actuated three-position valves that are controlled by the user from outside the hotcell.
The synthetic steps of the optimized sequence with respective reaction conditions are shown in Scheme 1.
Briefly 18 F]FBA off the cartridge but turned out to be problematic during the subsequent bromination step (vide infra). Et 2 O was successfully replaced with 3 ml of dry DCM, but a second elution with 1 ml of DCM was necessary to sufficiently release [ 18 F]FBA off the Oasis WCX. Since a proton source is necessary to form the OHfunctionality from the alcoholate obtained in the reduction of aldehydes with hydride, up to 38 % of the starting activity remained in the NaBH 4 bulk when extra dry DCM was used. This was addressed by adding a small amount of water (0.2 % v/v) to the second 1-ml elution with DCM to rinse the column. With this, only 1-3 % of the starting activity remained in the NaBH 4 bulk at the end of the synthesis. Efficient reduction of the aldehyde with conversion rates of 83-98 % was confirmed by analytical radio-HPLC in lowactivity runs (Suppl. Fig. 4 2 O with DCM during the on-column reduction avoided the formation of a biphasic system as well as precipitation of by-products derived from Ph 3 PBr 2 . Moreover, weighing the Ph 3 PBr 2 solution in a glovebox, and adding the dry solvent shortly before the start of the sequence to the septum-sealed vial of the reagent resulted in a more reliable bromination efficiency. Dry conditions have been reported to be a crucial requirement for high bromination yields [24] and strong fuming was observed if the brominating reagent was kept in an open vessel. To further increase the dryness of DCM coming from the preceding reduction step, the amount of K 2 CO 3 in the column was increased from 0.5 to 2 g. With these measures in place, up to 88 % bromination of [ 18 F]FBnOH was observed as confirmed by radio-HPLC in low-activity test runs (Suppl. Fig. 5 ). Less than 8 % leftover activity on the silica cartridge after purification was an additional indicator of good conversion rates in this step. Fig. 6 ).
Purification and Formulation of [ 18 F]FBnTP
Initially, the crude mixture was purified by semipreparative HPLC. The bulk of unreacted Ph 3 PBr 2 and PPh 3 were removed with a Sep-Pak C18 Plus Short cartridge and the resultant mixture was injected into the HPLC system. After collection of fractions containing the desired product and removal of solvent with a rotary evaporator, the probe was reformulated in saline. Problems associated with this approach were loss of product activity to the C18 cartridge, difficulties to remove residual Ph 3 PBr 2 that elutes shortly after [ 18 F]FBnTP under reversed phase conditions, and stickiness of the probe to the flask after removal of the HPLC-solvent. Formulations suffered from low chemical purities and low pH, both of which can be attributed to residual Ph 3 PBr 2 . The cationic nature of [
18 F]FBnTP led to use an analytical SCX HPLC column for the determination of A m and resulted in a well separated UV signal of the product. UV and radio-impurities eluted at considerably earlier retention times than the cationic product activity, allowing for an accurate determination of AUC for A m measurements. This led us to consider using a cation exchange cartridge for purification instead of HPLC, similar to a previously reported use of SPE purification for a cationic probe with a Sep-Pak Plus Accell CM cartridge [25] . In several radioactive and nonradioactive test runs, we optimized conditions to trap and wash [ 18 F]FBnTP on the Sep-Pak. The probe was efficiently trapped on the Accell CM even in the presence of large amounts of Ph 3 PBr 2 , PPh 3 , and other impurities, making the prepurification requirement obsolete. Trapping was achieved in a nearly quantitative manner by diluting the organic solvent in the last step (MeCN or EtOH) with water (water/solvent 9 7). Water can function as an activator of the carboxylic acid functionality on the Accell CM resin to enable binding with the cationic probe. After trapping of [ 18 F]FBnTP, the Sep-Pak was washed with EtOH to remove all noncationic radioactive and nonradioactive impurities without any notable losses (Suppl. Fig. 7 ). While elution with 0.9 % saline proved inadequate for complete release of [ 18 F]FBnTP,~90 % elution was achieved by increasing the ionic strength of saline with 0.5 % (w/v) Na-ascorbate which also stabilized the final formulation against radiolytic decomposition. The probe was obtained in RCP 9 99 % and high chemical purity (Suppl. Fig. 9 ). The purification process from the end of the synthetic sequence to the final formulation took less than 4 min. Unfortunately, considerable radiolysis of the probe was observed during Sep-Pak purification when starting with 23.2-33.0 GBq [
18 F]fluoride. Analysis of the activity that had passed through the Accell CM revealed a radiosignal of an unidentified, nonionic radiolysis product that accounted for up to 87 % of the waste activity and was not observed in low-activity runs. Addition of radical scavengers such as Naascorbate, ascorbic acid, and N-tert-butyl-α-phenylnitrone (PBN) [22] or reservatrol-3-β-mono-D-glucoside (polydatin) [26] either prevented trapping of [ 18 F]FBnTP on the Accell CM or did not hinder radiolysis. Trapping efficiencies were low in pure EtOH and water is known to facilitate radiolysis [22] . We therefore considered activation of the Sep-Pak with hydroxide or organic bases prior to purification in the absence of water but the trapping efficiencies remained low. Consequently, RCY of 28.6 ± 5.1 % (n = 3) were observed with starting activities of up to 12.0 GBq, whereas starting activities reaching 33.0 GBq resulted in lower RCY of 16.1 ± 0.4 % (n = 3). Despite the radiolytic decomposition during purification, the highest AY of 3.0 GBq was obtained from 33.0 GBq [
18 F]fluoride. Considerable higher AY will be achieved if radiolysis can be prevented in the final step. The probe was used in small animal imaging studies which will be reported elsewhere. Representative maximum intensity projection images of [ 18 F]FBnTP in a wild-type mouse are shown in the Supplementary Material (Suppl. Fig. 10 ).
Clinical Quality Control
Formulations of the probe in 2 % (v/v) EtOH in saline + 0.5 % (w/v) Na-ascorbate were subjected to a quality control established at the UCLA Ahmanson Biomedical Cyclotron Facility in accordance with the U.S. Pharmacopeia. RCP at the end of synthesis was 9 99 % and remained 9 95 % for at least 8 h. Chemical purity was estimated to be high (Suppl. Fig. 9 ). Doses were clear, colorless, and free of particulate matter with pH ranging from 5.0 to 5.8. Half-life of doses matched that of fluorine-18 (109.8 min) and energy of gamma rays was 511 keV. No kryptofix-222 (K 222 ) levels were observed with the spot test. Since the presence of Naascorbate gave false positive results, samples were spotted on a silica plate and developed in a mixture of methanol and 30 % ammonium hydroxide (9:1) prior to placing the plate in the iodine chamber. Other than the purposely added EtOH, no residual solvents were detected by gas chromatography. Sterile filters were intact after use. Doses contained G 175 endotoxin units (EU) per ml and no growth was observed at days 3, 7, and 14 as required to pass the sterility test.
Conclusion
A robust synthesis protocol for the production of multiple doses of the potentiometric PET probe [ 18 F]FBnTP was established on the ELYXIS FLEX/CHEM radiosynthesizer. Purification and formulation was achieved in G 4 min with a Sep-Pak Accell CM cartridge. RCY of 28.6 ± 5.1 % (n = 3) were obtained which is a significant improvement to previous reports. Despite our best efforts, radiolysis was not prevented in the final purification step when starting activities exceeded 12.0 GBq 
